These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 35291856)
1. Clinical value of O-RADS combined with serum CA125 and HE4 for the diagnosis of ovarian tumours. Wang R; Li X; Li S; Fang S; Zhao C; Yang H; Yang Z Acta Radiol; 2023 Feb; 64(2):821-828. PubMed ID: 35291856 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic performance of IOTA SR and O-RADS combined with CA125, HE4, and risk of malignancy algorithm to distinguish benign and malignant adnexal masses. Yang Y; Ju H; Huang Y Eur J Radiol; 2023 Aug; 165():110926. PubMed ID: 37418798 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance of CA125, HE4, ROMA, and CPH-I in identifying primary ovarian cancer. Luo HJ; Hu ZD; Cui M; Zhang XF; Tian WY; Ma CQ; Ren YN; Dong ZL J Obstet Gynaecol Res; 2023 Mar; 49(3):998-1006. PubMed ID: 36609691 [TBL] [Abstract][Full Text] [Related]
4. Revised Cut-Off Value of Human Epididymis Protein 4 Enhances Its Use as an Ovarian Tumor Marker. Machida H; Hirakawa T; Tsunekawa K; Kimura T; Murakami M; Abe Y Gynecol Obstet Invest; 2023; 88(6):349-358. PubMed ID: 37788640 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses. Xie WT; Wang YQ; Xiang ZS; Du ZS; Huang SX; Chen YJ; Tang LN J Ovarian Res; 2022 Jan; 15(1):15. PubMed ID: 35067220 [TBL] [Abstract][Full Text] [Related]
6. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma]. Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635 [TBL] [Abstract][Full Text] [Related]
7. CA125 and HE4: Measurement Tools for Ovarian Cancer. Zhao T; Hu W Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726 [TBL] [Abstract][Full Text] [Related]
8. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475 [TBL] [Abstract][Full Text] [Related]
9. Exosomal biomarkers in the differential diagnosis of ovarian tumors: the emerging roles of CA125, HE4, and C5a. Shi H; Liu L; Deng X; Xing X; Zhang Y; Djouda Rebecca Y; Han L J Ovarian Res; 2024 Jan; 17(1):4. PubMed ID: 38178252 [TBL] [Abstract][Full Text] [Related]
10. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125. Li W; Wang D Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526 [TBL] [Abstract][Full Text] [Related]
11. [Diagnostic value of CA125, HE4 and Copenhagen Index in differentiating benign from malignant epithelial ovarian tumors]. Gong SP; Chen YN; Zhang YD; Yao W; Chen L; Liu SS; Wu H Nan Fang Yi Ke Da Xue Xue Bao; 2017 May; 37(5):628-632. PubMed ID: 28539285 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis. Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074 [TBL] [Abstract][Full Text] [Related]
13. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence. Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083 [TBL] [Abstract][Full Text] [Related]
14. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses. Terlikowska KM; Dobrzycka B; Witkowska AM; Mackowiak-Matejczyk B; Sledziewski TK; Kinalski M; Terlikowski SJ J Ovarian Res; 2016 Jul; 9(1):43. PubMed ID: 27436085 [TBL] [Abstract][Full Text] [Related]
15. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy]. Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334 [TBL] [Abstract][Full Text] [Related]
16. HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients. Braicu EI; Krause CL; Torsten U; Mecke H; Richter R; Hellmeyer L; Lanowska M; Müller B; Koch E; Boenneß-Zaloum J; Ames K; Chekerov R; Hasenbein K; Zimmermann M; Mangler M; Chen F; Tauber R; Sehouli J BMC Cancer; 2022 Jul; 22(1):831. PubMed ID: 35907794 [TBL] [Abstract][Full Text] [Related]
17. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214 [TBL] [Abstract][Full Text] [Related]
18. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Ortiz-Muñoz B; Aznar-Oroval E; García García A; Covisa Peris A; Perez Ballestero P; Sanchez Yepes M; Garcia Lozano T; Illueca Ballester C; García Garcia E Tumour Biol; 2014 Jul; 35(7):7249-58. PubMed ID: 24771264 [TBL] [Abstract][Full Text] [Related]
19. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass]. Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150 [TBL] [Abstract][Full Text] [Related]
20. HE4 combined with CA125: favorable screening tool for ovarian cancer. Ghasemi N; Ghobadzadeh S; Zahraei M; Mohammadpour H; Bahrami S; Ganje MB; Rajabi S Med Oncol; 2014 Jan; 31(1):808. PubMed ID: 24323399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]